Lotus Simplifies Pharmaceutical Manufacturing

Lotus Logo

Despite major advancements in biopharmaceutical manufacturing, protein purification remains one of the most costly and restrictive aspects of production that impacts negatively impacting start-ups and Fortune 500 companies alike. 

At BMB, we are tackling this challenge by developing the Lotus® platform which links downstream contaminating host cell proteins (HCPs) to potential upstream cell line modifications.  The Lotus platform accomplishes this by identifying the cellular proteins that exert the greatest burden on downstream processing and then shutting off these genes in the production strain. This platform could be readily implemented across much of the biomanufacturing industry, with the potential to reduce costs to consumers in the ever-burgeoning healthcare market and ease the time and investment required to bring new therapeutics to market.

 BMB is currently supported by a National Science Foundation Phase I STTR grant which supports the development of the Lotus technology. The goal of the current project is to translate the current Lotus platform into a single plasmid construct that uses CRISPR to silence expression of the most burdensome HCPs that are encountered while purifying protein therapeutics via ion exchange chromatography. The resulting construct could be readily incorporated into virtually any Escherichia coli strain, offering a simple add-on to both commercialized and proprietary production strains. The planned outcome of the proposed Phase I work is a minimal viable product that substantially boosts the capture and purity of a representative biotherapeutic protein purified via ion-exchange chromatography. The associated construct will coordinately and completely turn off the expression of contaminating, non-essential genes and finely tune the expression of contaminating, essential genes to improve target capture and purity while preserving cell growth. 

How Can Lotus Help You?

 

Why We Created Lotus

 

Lotus Technical Data